Feb 10 (Reuters) - AstraZeneca on Thursday forecast
higher 2022 sales after the drugmaker posted
better-than-expected fourth-quarter profit as it gets a lift
from its COVID-19 antibody treatment.
The drugmaker, however, like rival GSK, warned that
its gross profit margin from coronavirus products is expected to
be lower than the company average for this year, while sales are
expected to decline by a low-to-mid twenties percentage.
(Reporting by Pushkala Aripaka in Bengaluru and Ludwig Burger
in Frankfurt; editing by Jason Neely)